PolyPid says FDA accepts D-PLEX100 NDA, grants priority review

Reuters2026/07/29 12:31

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA accepted PolyPid’s NDA for D-PLEX100 to prevent surgical-site infections in abdominal colorectal surgery, granting Priority Review.
PDUFA target action date set for Nov. 28, 2026, about one quarter earlier than prior guidance.
Acceptance triggers a USD 15 million milestone payment from Azurity, completing USD 30 million in upfront and near-term milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290830PRIMZONEFULLFEED9800147) on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PolyPid says FDA accepts D-PLEX100 NDA, grants priority review

You may also like

Crypto prices